Aubagio (teriflunomide) is a prescription drug used to treat some types of multiple sclerosis (MS), including clinically isolated syndrome (CIS). Aubagio can cause side effects that range from mild to ...

Aubagio (generic) is a prescription drug that’s used to treat multiple sclerosis (MS). This drug can interact with other medications. For example, Aubagio can interact with statins, such as ...

Aubagio is a brand-name oral tablet prescribed for relapsing forms of multiple sclerosis in adults. It contains the active ingredient teriflunomide. Aubagio is not safe to take during pregnancy. Keep ...

The TOWER pivotal phase III trial evaluated Aubagio in two dosage strengths, 7mg and 14mg. Patients in the 14mg dosage Aubagio arm demonstrated a 36.3% reduction in annualized relapse rate compared to ...

Sanofi SNY announced that the European Commission has approved Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis (“RRMS”) in pediatric patients aged 10 to 17 years.

Aubagio has been authorised for the treatment of paediatric patients aged ten to 17 years living with RRMS The European Commission has approved Sanofi’s oral multiple sclerosis (MS) therapy Aubagio ...

Sanofi SA has won U.S. approval for its multiple sclerosis pill Aubagio - one of the two treatments for the chronic disease that could return the French drugmaker to growth after several blockbuster ...

- Depth and Breadth of Data from the Genzyme MS Franchise Underscore Company’s Commitment to Addressing Unmet Needs of People Living with Multiple Sclerosis - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...

The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya. The most obvious competitors for Sanofi’s ...

As with other drugs, Aubagio (teriflunomide) can cause side effects, such as headache and diarrhea. If side effects of Aubagio become difficult to tolerate, talk with your doctor or pharmacist.

Sanofi SNY announced that the European Commission has approved Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis (“RRMS”) in pediatric patients aged 10 to 17 years.